(-)-P7C3-S243 是一种具有口服活性、可穿过血脑屏障的神经保护剂,能结合 μ-阿片受体 (Opioid Receptor) 和 TSPO,抑制新生海马神经元的过早凋亡 (apoptosis) 性死亡,保护成熟黑质多巴胺能神经元,促进神经元存活并预防认知障碍,在大鼠模型中改善抑郁样行为,可用于帕金森病和阿尔茨海默病的相关研究。
产品编号: MS-B43991 CAS No.: 1597443-57-6 分子式: C21H18Br2FN3O 分子量: 507.19
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

(-)-P7C3-S243 是一种具有口服活性、可穿过血脑屏障的神经保护剂,能结合 μ-阿片受体 (Opioid Receptor) 和 TSPO,抑制新生海马神经元的过早凋亡 (apoptosis) 性死亡,保护成熟黑质多巴胺能神经元,促进神经元存活并预防认知障碍,在大鼠模型中改善抑郁样行为,可用于帕金森病和阿尔茨海默病的相关研究。

生物实验数据

生物活性 (-)-P7C3-S243 is an orally active, blood-brain barrier-penetrant neuroprotective agent that binds to the μ-opioid receptor (Opioid Receptor) and TSPO, inhibits premature apoptotic (apoptosis) death of newborn hippocampal neurons, protects mature substantia nigra dopaminergic neurons, promotes neuronal survival and prevents cognitive impairment, ameliorates depression-like behavior in rat models, and can be used in research related to Parkinson's disease and Alzheimer's disease.
体外研究
(In Vitro)

(-)-P7C3-S243 (Compound 15) 可在体外轻度抑制 CYP1A2 (IC50 = 20 μM) 和 CYP2C19 (IC50 = 1.9 μM),但对其他多种受试 CYP 亚型无抑制作用。
(-)-P7C3-S243 可在体外结合 μ-阿片受体 (IC50 = 8.2 μM) 和 TSPO (IC50 = 0.35 μM),但不与大多数其他受试神经元受体及通道结合。

体内研究
(In Vivo)

(-)-P7C3-S243 ( 10 μM (12 μL/day)/0.1-10 mg/kg/天;i.c.v./i.p.;每日 2 次;7 天) 可使环境匮乏小鼠体内存活的新生海马神经元数量增加一倍,提高海马神经元的存活率
(-)-P7C3-S243 (1-10 mg/kg;腹腔注射;每日 2 次;连续 21 天) 可剂量依赖性地保护经 MPTP (MS-P76578) 处理小鼠黑质中的成熟多巴胺能神经元。
(-)-P7C3-S243 (10 mg/kg;腹腔注射;10 天) 可使 TgF344-AD 大鼠的出生后海马神经发生水平提升 1 倍,保护大鼠免受早期类抑郁行为和晚期认知损伤的影响,减少神经退行性变和神经元丢失,同时还可改善野生型大鼠的年龄相关性类抑郁行为。

Animal Model: C57BL/J6 (12-week-old)
Dosage: 10 μM; 0.1-10 mg/kg/day
Administration: i.c.v.; 0.5 μL/h; 7 days; i.p.; BID; 7 days
Result: Approximately doubled the number of surviving BrdU+ newborn hippocampal neurons compared to vehicle-treated mice.
Showed a smooth dose-response curve, with activity detectable at 1 mg/kg/day and maximum efficacy achieved at 10 mg/kg/day; efficacy reflected increased survival of newborn hippocampal neurons via neuroprotection (not increased proliferation).
Animal Model: C57Bl/6 (adult male; MPTP-induced Parkinson's disease)
Dosage: 1, 3, 5, 10 mg/kg/day
Administration: i.p.; BID; 21 days
Result: Showed significant neuroprotective activity at 1 mg/kg/day, and at the highest tested dose of 10 mg/kg/day, rescued over 85% of TH+ dopaminergic neurons in the substantia nigra (compared to MPTP-treated vehicle controls).; Demonstrated higher efficacy than that of P7C3-A20, with strict enantiomeric specificity (only the (−)-S enantiomer was active).
Animal Model: Fischer 344 rats (male and female, 6 months old at treatment initiation; TgF344-AD transgenic overexpressing human mutant APP_SW and PS1ΔE9 genes; wild-type)
Dosage: 10 mg/kg/d
Administration: daily; 9 months (15-month assessments); 18 months (24-month assessments)
Result: Reduced time spent immobile in the Porsolt forced swim test in TgF344-AD rats to levels comparable to WT animals at 15 months.
Did not affect locomotor activity or cause cognitive deficits in any group at 15 months.
Improved performance in the Morris water maze reversal memory probe in TgF344-AD rats, reducing time to locate the target position to levels similar to WT animals at 24 months.
Ameliorated depression-like behavior in 24-month-old WT rats, reducing time spent immobile in the Porsolt forced swim test from mean 45 seconds to mean 20 seconds (p=0.0176), but did not correct depression-like behavior in 24-month-old TgF344-AD rats.
Significantly reduced vacuole formation in the hippocampus and cerebral cortex of TgF344-AD rats at 24 months.
Prevented neuronal cell loss in the hippocampus and cerebral cortex, and increased neuronal cell counts in the dentate gyrus granule cell layer of TgF344-AD rats at 24 months.
Did not alter amyloid plaque deposition, levels of soluble or insoluble Aβ1-40/Aβ1-42 peptides, tau hyperphosphorylation (Tau PS199/202), or glial activation (GFAP+ astrocytes or Iba1+ microglia) in TgF344-AD rats at 24 months.

化学信息

分子量 507.19
分子式 C21H18Br2FN3O
CAS No. 1597443-57-6

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础